Ignite Creation Date:
2024-05-06 @ 10:06 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03164603
Status:
COMPLETED
Last Update Posted:
2020-06-04
First Post:
2017-05-22
Brief Title:
NLG802 Indoleamine 23-Dioxygenase IDO Inhibitor in Advanced Solid Tumors
Sponsor:
NewLink Genetics Corporation
Organization:
Lumos Pharma
Study Overview
Official Title:
A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2020-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label Phase I study to evaluate the safety tolerability and pharmacokinetics of escalating oral doses of NLG802 an investigational agent intended to inhibit the indoleamine 23-dioxygenase 1 IDO1 enzyme and help the human immune system attack solid tumor cells more effectively
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None